Podcasts about Cancer research

EPISODE DESCRIPTIONRebecca V. Nellis never meant to run a nonprofit. She just never left. Twenty years later, she's still helming Cancer and Careers after a Craigslist maternity-leave temp job turned into a lifelong mission.In this 60-minute doubleheader, we cover everything from theater nerdom and improv rules for surviving bureaucracy, to hanging up on Jon Bon Jovi, to navigating cancer while working—or working while surviving cancer. Same thing.Rebecca's path is part Second City, part Prague hostel, part Upper East Side grant writer, and somehow all of that makes perfect sense. She breaks down how theater kids become nonprofit lifers, how “sample sale feminism” helped shape a cancer rights org, and how you know when the work is finally worth staying for.Also: Cleavon Little. Tap Dance Kid. 42 countries. And one extremely awkward moment involving a room full of women's handbags and one very confused Matthew.If you've ever had to hide your diagnosis to keep a job—or wanted to burn the whole HR system down—this one's for you.RELATED LINKSCancer and CareersRebecca Nellis on LinkedIn2024 Cancer and Careers Research ReportWorking with Cancer Pledge (Publicis)CEW FoundationI'm Not Rappaport – Broadway InfoFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship opportunities, email podcast@matthewzachary.com.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Yossi Matias is the head of Google Research. He joins Big Technology Podcast to discuss the company's research efforts in areas like cancer treatment and Quantum and to discuss the relationship between research and product. Tune in to hear how Google used LLMs to generate a cancer hypothesis validated in living cells, what a “13,000×” quantum result really means, and how the research product loop turns papers into products. We also cover whether AI can automate a researcher's job. This conversation was recorded in front of a live audience at Google's Mountain View headquarters. --- Enjoying Big Technology Podcast? Please rate us five stars ⭐⭐⭐⭐⭐ in your podcast app of choice. Want a discount for Big Technology on Substack + Discord? Here's 25% off for the first year: https://www.bigtechnology.com/subscribe?coupon=0843016b Questions? Feedback? Write to: bigtechnologypodcast@gmail.com

What are the latest advances in lung cancer treatment? In April 2022, findings from the large scale CheckMate 816 clinical trial were presented to the American Association for Cancer Research. The trial looked into the effectiveness of immunotherapy drug Nivolumab, combined with chemotherapy to treat lung cancer patients. The findings were promising, showing that this particular treatment combination can delay the progression or return of cancer.  How common is lung cancer and how does it start? What are the most prominent treatment options? Should we expect this treatment to become used widely?  ⁠In under 3 minutes, we answer your questions !⁠ To listen to the last episodes, you can click here : ⁠What is Roe vs Wade, the ruling that guaranteed American women abortion rights?⁠ ⁠Could tourism quotas help preserve endangered local environments?⁠ ⁠Is bikini waxing harmful for your health?⁠ A podcast written and realised by Joseph Chance. First Broadcast: 9/7/2022 Learn more about your ad choices. Visit megaphone.fm/adchoices

"Robot Roommate" Hosts: Darren Weeks, Vicky Davis Website for the show: https://governamerica.com Vicky's website: https://thetechnocratictyranny.com COMPLETE SHOW NOTES AND CREDITS AT: https://governamerica.com/radio/radio-archives/22640-govern-america-october-25-2025-robot-roommate Listen LIVE every Saturday at 11AM Eastern or 8AM Pacific at http://governamerica.net or on your favorite app. SNAP program threatened due to government shutdown. World Economic Forum promotes "No Till" farming. Panelist at WEF says robots will live among us in five years. Cancer research and national health databases. UK's Keir Starmer continues with Digital ID plans, despite massive opposition by the People. Real ID and the National Animal ID System were components of U.S. Digital ID implementation. E-Verify will not fix the illegal alien problem, but will give the government more power over everyone! Trump administration thwarts proposed carbon tax on shipping. Michigan students don't meet standards for reading, and more.

In this episode of the Bench to Bedside podcast, Dr. Roy Jensen, vice chancellor and director of The University of Kansas Cancer Center, speaks with Dr. Ronald Chen, chair of Radiation Oncology and associate director for Community Outreach and Engagement at KU Cancer Center. Dr. Chen shares his personal and professional journey from growing up in Topeka to Harvard and a career on the East Coast and back to Kansas, focusing on his motivation to return home and how his work impacts rural communities. He discusses his efforts in cancer care, telehealth and clinical trials, emphasizing the importance of bringing skills back to Kansas to improve local healthcare. 00:00 Introduction to Bench to Bedside 00:47 Meet Dr. Ron Chen 01:33 Dr. Chen's Educational Journey 03:41 Returning to Kansas 05:40 Advice for Young Kansans 07:19 Midwest Reflections 09:50 Addressing Rural Healthcare Challenges 12:35 Community Engagement and Partnerships 14:46 Balancing Clinical Care and Research 17:02 Future of Cancer Care at KU 19:30 Conclusion and Farewell Links from this Episode: ·       Learn more about Dr. Ronald Chen ·       Read this Q&A with Dr. Chen focused on eliminating health disparities ·       Learn more about community outreach and engagement at KU Cancer Center ·       Read about the Masonic Cancer Alliance To ensure you get our latest updates, follow us on the social media channel of your choice by searching for KU Cancer Center.

Sally Wolf is back in the studio and this time we left cancer at the door. She turned 50, brought a 1993 Newsday valedictorian article as a prop, and sat down with me for a half hour of pure Gen X therapy. We dug into VHS tracking, Red Dawn paranoia, Michael J. Fox, Bette Midler, and how growing up with no helmets and playgrounds built over concrete somehow didn't kill us.We laughed about being Jewish kids in the suburbs, the crushes we had on thirty-year-olds playing teenagers, and what it means to hit 50 with your humor intact. This episode is part nostalgia trip, part roast of our own generation, and part meditation on the privilege of being alive long enough to look back at it all. If you ever watched Different Strokes “very special episodes” or had a Family Ties lunchbox, this one's for you.RELATED LINKSSally Wolf Official WebsiteSally Wolf on LinkedInSally Wolf on InstagramCosmopolitan Essay: “What It's Like to Have the ‘Good' Cancer”Oprah Daily: “Five Things I Wish Everyone Understood About My Metastatic Breast Cancer Diagnosis”Allure Breast Cancer Photo ShootTom Wilson's “Stop Asking Me the Question” SongFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship inquiries, email podcast@matthewzachary.com.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Assistant Secretary for Technology Policy Chief of Innovation and Strategic Partnerships Stephen Konya has been credited with launching groundbreaking initiatives like CancerX to accelerate innovation in health care. These efforts are largely borne out of partnerships with the private sector, including academia, entrepreneurs, investors, developers and more. Konya shared how he's building innovation ecosystems that stay rooted in patient needs while advancing cutting-edge technologies. He highlighted how connecting innovation networks to resources can also expand patient access to care. Drawing on his experience leading Federal Innovation Days and spearheading interagency collaborations, Konya offered lessons on translating federal innovation into real-world impact. He also explored the biggest barriers to access, strategies for sustaining innovation and the emerging technologies shaping the future of health care.

There's no denying veganism is better for the environment, and it can be better for your wallet. But there are some caveats, and health considerations. Get some facts this week in our episode on why you might consider going vegan and how to do it. SourcesNIH - https://pmc.ncbi.nlm.nih.gov/articles/PMC9024616/The Guardian - https://www.theguardian.com/environment/2023/jul/20/vegan-diet-cuts-environmental-damage-climate-heating-emissions-studyBBC - https://www.bbc.com/future/article/20200211-why-the-vegan-diet-is-not-always-greenAmerican Institute for Cancer Research - https://www.aicr.org/resources/blog/does-red-meat-cause-cancer/Weston A. Price - https://www.westonaprice.org/health-topics/abcs-of-nutrition/the-china-study-myth/#gsc.tab=0NIH - https://pmc.ncbi.nlm.nih.gov/articles/PMC9321292/NIH - https://pmc.ncbi.nlm.nih.gov/articles/PMC10027313/Patreon: patreon.com/greeningupmyactInstagram: @greeningupmyactFacebook: Greening Up My ActEmail us with questions: greeningupmyact@gmail.comYouTube: Greening Up My Act

Pippa Hudson speaks to Samantha Loggenberg, who is a University of Pretoria PhD candidate, an is among eight female scientists awarded The L’Oréal-UNESCO For Women in Science Award for her investigation of South African medicinal plants to find new compounds that could help treat triple-negative breast cancer. Lunch with Pippa Hudson is CapeTalk’s mid-afternoon show. This 2-hour respite from hard news encourages the audience to take the time to explore, taste, read and reflect. The show - presented by former journalist, baker and water sports enthusiast Pippa Hudson - is unashamedly lifestyle driven. Popular features include a daily profile interview #OnTheCouch at 1:10pm. Consumer issues are in the spotlight every Wednesday while the team also unpacks all things related to health, wealth & the environment. Thank you for listening to a podcast from Lunch with Pippa Hudson Listen live on Primedia+ weekdays between 13:00 and 15:00 (SA Time) to Lunch with Pippa Hudson broadcast on CapeTalk https://buff.ly/NnFM3Nk For more from the show, go to https://buff.ly/MdSlWEs or find all the catch-up podcasts here https://buff.ly/fDJWe69 Subscribe to the CapeTalk Daily and Weekly Newsletters https://buff.ly/sbvVZD5 Follow us on social media: CapeTalk on Facebook: https://www.facebook.com/CapeTalk CapeTalk on TikTok: https://www.tiktok.com/@capetalk CapeTalk on Instagram: https://www.instagram.com/ CapeTalk on X: https://x.com/CapeTalk CapeTalk on YouTube: https://www.youtube.com/@CapeTalk567 See omnystudio.com/listener for privacy information.

In this edition of SSAT Mentor Spotlight, Dr. Praveen Chatani, Surgical Oncologist Fellow at Fox Chase Cancer Center, and Dr. Raja Narayan, Assistant Professor at Loma Linda University and both members of the Resident and Fellow Education Committee, interview Dr. Syed Ahmad,  the Cancer Center Co-Director, Hayden Family Endowed Chair for Cancer Research, Professor of Surgery, and Chief of the Division of Surgical Oncology at the University of Cincinnati, and Dr. Michael D'Angelica, Vice Chair of Education, Enid A. Haupt Chair in Surgery, and Emeritus Program Director for the HPB and Surgical Oncology Fellowships at Memorial Sloan Kettering Cancer Center as well as Professor of Surgery at Cornell. 

Dr. Nikki Maphis didn't just lose a grant. She lost a lifeline. An early-career Alzheimer's researcher driven by her grandmother's diagnosis, Nikki poured years into her work—only to watch it vanish when the NIH's MOSAIC program got axed overnight. Her application wasn't rejected. It was deleted. No feedback. No score. Just gone.In this episode, Oliver Bogler pulls back the curtain on what happens when politics and science collide and promising scientists get crushed in the crossfire. Nikki shares how she's fighting to stay in the field, teaching the next generation, and rewriting her grant for a world where even the word “diversity” can get you blacklisted. The conversation is raw, human, and maddening—a reminder that the real “war on science” doesn't happen in labs. It happens in inboxes.RELATED LINKS:• Dr. Nikki Maphis LinkedIn page• Dr. Nikki Maphis' page at the University of New Mexico• Vanguard News Group coverage• Nature article• PNAS: Contribution of NIH funding to new drug approvals 2010–2016FEEDBACK:Like this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship inquiries, visit outofpatients.com.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

In this episode of the Vital Health Podcast, host Duane Schulthess speaks with three leaders advancing precision cancer medicine implementation in Europe: Bettina Ryll: Stockholm School of Economics, Institute for Research; Founder, Melanoma Patient Network Europe. Kjetil Taskén: Head of the Institute for Cancer Research, Oslo University Hospital; Professor, University of Oslo; Coordinator, PRIME-ROSE. Anni Lepland: Head of Personalized Medicine in Oncology, Estonian Cancer Network. They explore how Europe’s new Joint Action can accelerate equitable precision oncology, what PRIME-ROSE has learned from aggregating data across national pragmatic trials, and why a distributed, bottom-up model with strong patient involvement and industry collaboration is key to scaling access and evidence generation across member states. Key Topics: EU Joint Action: Governmental collaboration, precision prevention, diagnosis, and treatment, precision follow-up. PRIME-ROSE Collaboration: Data sharing agreements, aggregated cohorts, common biomarker definitions, and monthly alignment. Patient Need First: Options after standard care, access to molecular profiling, pragmatic protocols, and learning from each case. Widening Country Gaps: Workforce shortages, national coordination, digital tools, and equitable access to innovative drugs. Industry and Access: Single point of entry for drugs, managed entry agreements, off-label registries, and scaling trials across Europe. Opinions expressed are those of the speakers.See omnystudio.com/listener for privacy information.

Carla Tardiff has spent 17 years as the CEO of Family Reach, a nonprofit that shouldn't have to exist but absolutely does—because in America, cancer comes with a price tag your insurance doesn't cover.We talk about shame, fear, burnout, Wegmans, Syracuse, celebrity telethons, and the godforsaken reality of choosing between food and treatment. Carla's a lifer in this fight, holding the line between humanity and bureaucracy, between data and decency. She's also sharp as hell, deeply funny, and more purpose-driven than half of Congress on a good day.This episode is about the work no one wants to do, the stuff no one wants to say, and why staying angry might be the only way to stay sane.Come for the laughs. Stay for the rage. And find out why Family Reach is the only adult in the room.RELATED LINKSFamily ReachFinancial Resource CenterCarla on LinkedInMorgridge Foundation ProfileAuthority Magazine InterviewSyracuse University FeatureFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship inquiries, email podcast@matthewzachary.com.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Anthony Scaramucci and Brittany Kaiser explain how AlphaTON are using digital assets to fund cancer research and launch companies within blockchain and the “Telegram ecosystem.” AlphaTON (ATON) owns multiple molecules and is looking for “innovative ways” to combine their biotech knowledge with financial systems expertise. Brittany notes that it is hard to raise money for biotech right now, but it's easy to fundraise for digital assets.======== Schwab Network ========Empowering every investor and trader, every market day.Subscribe to the Market Minute newsletter - https://schwabnetwork.com/subscribeDownload the iOS app - https://apps.apple.com/us/app/schwab-network/id1460719185Download the Amazon Fire Tv App - https://www.amazon.com/TD-Ameritrade-Network/dp/B07KRD76C7Watch on Sling - https://watch.sling.com/1/asset/191928615bd8d47686f94682aefaa007/watchWatch on Vizio - https://www.vizio.com/en/watchfreeplus-exploreWatch on DistroTV - https://www.distro.tv/live/schwab-network/Follow us on X – / schwabnetwork Follow us on Facebook – / schwabnetwork Follow us on LinkedIn - / schwab-network About Schwab Network - https://schwabnetwork.com/about

In today's episode, leading experts across oncology specialties previewed the key studies and data they are most anticipating ahead of the 2025 ESMO Congress. Dana M. Chase, MD, a professor of Clinical Obstetrics and Gynecology in the Division of Gynecologic Oncology at UCLA, discussed her excitement to see findings from a phase 1 trial (NCT05403554) investigating NI-1801 in patients with heavily pretreated, mesothelin-expressing platinum-resistant epithelial ovarian cancer. Premal H. Thaker, MD, MS, the David G. and Lynn Mutch Distinguished Professor of Obstetrics and Gynecology and director of Gynecologic Oncology Clinical Research at Siteman Cancer Center in Saint Louis, Missouri, discussed the anticipation for findings from a multi-omic analysis of the phase 3 AtTEnd/ENGOT-EN7 trial (NCT03603184) of atezolizumab in patients with endometrial cancer and data demonstrating that the WES-derived Aneuploidy Score may identify patients with mismatch repair–deficient endometrial cancer who derive reduced benefit from immunotherapy. Zev Wainberg, MD, the Estelle, Abe, and Marjorie Sanders Chair in Cancer Research at UCLA, shared his anticipation for new data in gastrointestinal oncology, particularly the overall survival results from the phase 3 MATTERHORN trial (NCT04592913) of durvalumab plus fluorouracil, leucovorin, oxaliplatin, and docetaxel in patients with resectable gastric and gastroesophageal cancer, which are expected to provide pivotal updates following previously reported event-free survival outcomes. Sagus Sampath, MD, an associate clinical professor and medical director of the Department of Radiation Oncology at City of Hope in Duarte, California, highlighted the phase 2 NorthStar trial (NCT03410043) evaluating osimertinib (Tagrisso) with or without local consolidative therapy in patients with metastatic EGFR-mutated non–small cell lung cancer (NSCLC).

Anne Bodley is a breast cancer survivor who has benefited from a cancer research trial and is here to tell us her story. Also joining Pat along with Anne was Dr Claire Kilty Head of Research, the Irish Cancer Society.

Meet the scientists at the University of Minnesota who are finding new ways to treat one of the world's toughest diseases

In the 1970s, President Richard Nixon declared a “war on cancer.” Today, President Trump seems to be winding it down. Jonathan Mahler, staff writer for The New York Times Magazine, joins host Krys Boyd to discuss how Trump administration efforts to target suspected waste and abuse have shut down vital cancer research, how government funding helped make enormous strides in cancer survival rates, and what happens to patients who find themselves sick with a diagnosis now. His article is “Trump Is Shutting Down the War On Cancer.” Learn about your ad choices: dovetail.prx.org/ad-choices

In this episode of Disruption/Interruption, host KJ sits down with Jim Foote, CEO and founder of First Ascent Biomedical. Jim shares his personal journey from technology executive to cancer care innovator, after his son’s diagnosis changed his life. Discover how he’s disrupting the status quo in oncology with AI-driven, personalized medicine that’s giving new hope to patients and families. Key Takeaways: The Problem with Standard Cancer Care [3:53]The standard of care treats patients as if they are the same, but everyone is unique. This approach works two-thirds of the time, but leaves one-third of patients with few options. Functional Precision Medicine [13:04]Jim’s company tests up to 152 FDA-approved drugs on a patient’s biopsy to find the most effective treatment, providing doctors with data-driven options tailored to each individual. AI and Technology are Transforming Oncology [28:05]Advances in AI, robotics, and cloud computing have converged, making personalized cancer treatment faster, more affordable, and more effective than ever before. Impact and Future Vision [26:51]Jim’s goal is for every cancer patient to receive individualized treatment from the moment of diagnosis, improving outcomes and reducing unnecessary side effects. Quote of the Show (14:40):“I literally have gone from trying and hoping to testing and choosing.” — Jim Foote Join our Anti-PR newsletter where we’re keeping a watchful and clever eye on PR trends, PR fails, and interesting news in tech so you don't have to. You're welcome. Want PR that actually matters? Get 30 minutes of expert advice in a fast-paced, zero-nonsense session from Karla Jo Helms, a veteran Crisis PR and Anti-PR Strategist who knows how to tell your story in the best possible light and get the exposure you need to disrupt your industry. Click here to book your call: https://info.jotopr.com/free-anti-pr-eval Ways to connect with Jim Foote: LinkedIn: http://www.linkedin.com/in/jim-foote Company Website: https://firstascentbiomedical.com/ How to get more Disruption/Interruption: Amazon Music - https://music.amazon.com/podcasts/eccda84d-4d5b-4c52-ba54-7fd8af3cbe87/disruption-interruption Apple Podcast - https://podcasts.apple.com/us/podcast/disruption-interruption/id1581985755 Spotify - https://open.spotify.com/show/6yGSwcSp8J354awJkCmJlDSee omnystudio.com/listener for privacy information.

People under 50 are experiencing higher risk of some cancers. While overall cancer rates are declining, the incidence of 14 cancer types have increased in younger people. Why? It could be related to lifestyle choices, environmental factors, or an individual's genetics. In this episode, host Samantha Laine Perfas speaks with global cancer trend expert Tim Rebbeck, oncologist Kimmie Ng, and epidemiologist Tomotaka Ugai about how people under 50 can best mitigate their cancer risk.

Jennifer J. Brown is a scientist, a writer, and a mother who never got the luxury of separating those roles. Her memoir When the Baby Is Not OK: Hopes & Genes is a punch to the gut of polite society and a medical system that expects parents to smile through trauma. She wrote it because she had to. Because the people who gave her the diagnosis didn't give her the truth. Because a Harvard-educated geneticist with two daughters born with PKU still couldn't get a straight answer from the very system she trained in.We sat down in the studio to talk about the unbearable loneliness of rare disease parenting, the disconnect between medical knowledge and human connection, and what it means to weaponize science against silence. She talks about bias in the NICU, the failure of healthcare communication, and why “resilience” is a lazy word. Her daughters are grown now. One's a playwright. One's an artist. And Jennifer is still raising hell.This is a conversation about control, trauma, survival, and rewriting the script when the world hands you someone else's lines.Bring tissues. Then bring receipts.RELATED LINKS• When the Baby Is Not OK (Book)• Jennifer's Website• Jennifer on LinkedInFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship inquiries, visit outofpatients.show.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

It's Breast Cancer Awarness Month and for the 4th year in a row we're talking to some badass women! This year our featured badass is Anne Keane who we met earlier this year during our Boston Marathon Fundraising series!Anne (19:38) shares her journey of living with stage four cancer while actively participating in marathons. She discusses the importance of holistic healing, the support of her community, and how running has empowered her to face her challenges. The conversation highlights the transformative experiences in treatment and the impact of inspiring others through her story. In this engaging conversation, the speakers discuss the importance of running as a means of coping with personal challenges, particularly in relation to cancer awareness and fundraising efforts. They explore the authenticity of storytelling in sharing personal journeys, the significance of community support, and the joy of running. The conversation also touches on future aspirations, the role of family, and the impact of women's sports, all while maintaining a light-hearted atmosphere with trivia and fun anecdotes.During the Tros, Eric and Erika reconnect with their running community, celebrate personal achievements, and discuss their fundraising efforts for mental health awareness. They reflect on the growth of their podcast, share insights on running for a purpose, and navigate some issues they had when Erika missed an episode and almost quit the pod while maintaining a light-hearted atmosphere with trivia and fun moments. The episode concludes with plans for upcoming races and gratitude towards their listeners and sponsors.Chapters00:00 Welcome Back Six Star!03:10 The Journey of a 100-Miler13:48 Fundraising for a Cause19:32 Looking Ahead to Future Races19:38 Anne Keane | Breast Cancer Awareness Month23:06 Context of Cancer Treatment51:14 Progress in Cancer Research and Treatment54:07 The Journey of Running and Fundraising57:10 Boston Marathon59:58 Dana-Farber Cancer Institute01:05:56 Community and Support in Cancer Treatment01:11:49 Balancing Life and Running01:17:05 Preparing for Chicago Marathon01:30:45 Outro01:33:24 Podcast Growth and Listener Engagement01:36:24 Trivia Night and Podcast Dynamics01:38:51 Looking Ahead: Future Episodes and Events01:40:49 Planning Ahead: Chicago and Year-End Recap01:43:44 Trivia Time: Testing Knowledge and Fun01:48:04 Meetups and Events: Connecting with the Community01:51:15 Closing ThoughtMy Race Tatts Affiliate Page - 15% of your purchase goes towards our TEAM FORCE Fundraising efforts for the NYC Marathon Wrightsock Affiliate Page - 15% of your purchase goes towards our TEAM FORCE Fundraising efforts for the NYC Marathon Eric's NYC Marathon Fundraiser - Team FORCE, a dynamic organization that supports the hereditary cancer community Erika's Chicago Marathon Fundraiser - for American Foundation for Suicide Prevention in memory of her brother, Nick Strava GroupLinktree - Find everything hereInstagram - Follow us on the gram YouTube - Subscribe to our channel Patreon - Support usThreadsEmail us at OnTheRunsPod@gmail.com

Surgical resection of perihilar cholangiocarcinoma (pCCA) is one of the highest-risk elective operations performed. The obstructive jaundice suffered by patients preoperatively, central location of the tumors, and extensive nature of the resection make pCCA one of the most challenging HPB disease processes. In this episode from the HPB team at Behind the Knife, listen in on the discussion about perioperative strategies to improve outcomes for surgical resection of perihilar cholangiocarcinoma. Hosts Anish J. Jain MD (@anishjayjain) is a current PGY4 General Surgery Resident at Stanford University and a former T32 Research Fellow at the University of Texas MD Anderson Cancer Center. Timothy E. Newhook MD, FACS (@timnewhook19) is an Assistant Professor within the Department of Surgical Oncology at the University of Texas MD Anderson Cancer Center. He is also the associate program director of the HPB fellowship.  Jean-Nicolas Vauthey MD, FACS (@VautheyMD) is Professor of Surgery and Chief of the HPB Section, as well as the Dallas/Fort Worth Living Legend Chair of Cancer Research in the Department of Surgical Oncology at The University of Texas MD Anderson Cancer Center. Learning Objectives ·      Develop an understanding of the three treatment sequences for resection of disease in patients with synchronous liver metastasis from a primary rectal cancer (reverse, combined, and classic approach) ·      Develop an understanding of the benefits, risks, and nuances of each of the three treatment sequences ·      Develop an understanding of which patient cases each treatment sequence is ideal for as well as which cases they are not suitable for. Papers Referenced: 1)    Ribero D, Zimmitti G, Aloia TA, Shindoh J, Fabio F, Amisano M, Passot G, Ferrero A, Vauthey JN. Preoperative Cholangitis and Future Liver Remnant Volume Determine the Risk of Liver Failure in Patients Undergoing Resection for Hilar Cholangiocarcinoma. J Am Coll Surg. 2016 Jul;223(1):87-97. https://pubmed.ncbi.nlm.nih.gov/27049784/ 2)    Jain AJ, Lendoire M, Haddad A, Tzeng CD, Boyev A, Maki H, Chun YS, Arvide EM, Lee S, Hu I, Pant S, Javle M, Tran Cao HS, Vauthey JN, Newhook TE. Improved Outcomes Following Resection of Perihilar Cholangiocarcinoma: A 27-Year Experience. Ann Surg Oncol. 2025 Jun;32(6):4352-4362. https://pubmed.ncbi.nlm.nih.gov/40000564/ Additional Suggested Reading Olthof PB, Erdmann JI, Alikhanov R, Charco R, Guglielmi A, Hagendoorn J, Hakeem A, Hoogwater FJH, Jarnagin WR, Kazemier G, Lang H, Maithel SK, Malago M, Malik HZ, Nadalin S, Neumann U, Olde Damink SWM, Pratschke J, Ratti F, Ravaioli M, Roberts KJ, Schadde E, Schnitzbauer AA, Sparrelid E, Topal B, Troisi RI, Groot Koerkamp B; Perihilar Cholangiocarcinoma Collaboration Group. Higher Postoperative Mortality and Inferior Survival After Right-Sided Liver Resection for Perihilar Cholangiocarcinoma: Left-Sided Resection is Preferred When Possible. Ann Surg Oncol. 2024 Jul;31(7):4405-4412. https://pubmed.ncbi.nlm.nih.gov/38472674/ Mueller M, Breuer E, Mizuno T, Bartsch F, et al. Perihilar Cholangiocarcinoma - Novel Benchmark Values for Surgical and Oncological Outcomes From 24 Expert Centers. Ann Surg. 2021 Nov 1;274(5):780-788. https://pubmed.ncbi.nlm.nih.gov/34334638/ Ad Disclosures: Visit goremedical.com/btk to learn more about GORE® ENFORM Biomaterial. Refer to Instructions for Use at eifu.goremedical.com for a complete description of all applicable indications, warnings, precautions and contraindications for the markets where this product is available. Rx only Please visit https://behindtheknife.org to access other high-yield surgical education podcasts, videos and more.   If you liked this episode, check out our recent episodes here: https://behindtheknife.org/listen Behind the Knife Premium: General Surgery Oral Board Review Course: https://behindtheknife.org/premium/general-surgery-oral-board-review Trauma Surgery Video Atlas: https://behindtheknife.org/premium/trauma-surgery-video-atlas Dominate Surgery: A High-Yield Guide to Your Surgery Clerkship: https://behindtheknife.org/premium/dominate-surgery-a-high-yield-guide-to-your-surgery-clerkship Dominate Surgery for APPs: A High-Yield Guide to Your Surgery Rotation: https://behindtheknife.org/premium/dominate-surgery-for-apps-a-high-yield-guide-to-your-surgery-rotation Vascular Surgery Oral Board Review Course: https://behindtheknife.org/premium/vascular-surgery-oral-board-audio-review Colorectal Surgery Oral Board Review Course: https://behindtheknife.org/premium/colorectal-surgery-oral-board-audio-review Surgical Oncology Oral Board Review Course: https://behindtheknife.org/premium/surgical-oncology-oral-board-audio-review Cardiothoracic Oral Board Review Course: https://behindtheknife.org/premium/cardiothoracic-surgery-oral-board-audio-review Download our App: Apple App Store: https://apps.apple.com/us/app/behind-the-knife/id1672420049 Android/Google Play: https://play.google.com/store/apps/details?id=com.btk.app&hl=en_US

WBZ NewsRadio's Kyle Bray reports.

In this episode, I'm talking with Medha Kaul a research data analyst in the Division of Epidemiology at Mayo Clinic about her job and the research she is doing!

Osteosarcoma Webinar Series: Alanna Church, MD, Associate Director, Laboratory for Molecular Pediatric Pathology at Boston Children's Hospital, Assistant Professor of Pathology at Harvard Medical School, and Conference Cochair joins us on OsteoBites to discuss insights and higlights from the AACR Special Conference in Cancer Research: Discovery and Innovation in Pediatric Cancer—From Biology to Breakthrough Therapies, September 25-28 in Boston.Dr. Church is currently a Molecular and Pediatric Pathologist at Boston Children's Hospital, where she is a founder and associate medical director of the Laboratory for Molecular Pediatric Pathology (LaMPP). She is an Assistant Professor of Pathology at Harvard Medical School, the Program Director for the Harvard Molecular Genetic Pathology Fellowship, and the incoming Chair of Clinical Practice for the Association for Molecular Pathology. Her clinical and research work focuses on bringing molecular testing to the clinical care of children with cancer. Through institutional projects (the Profile study, GAIN consortium study), she has profiled thousands of children's tumors and has used these results to make real-time impacts on their diagnoses and treatments. She is involved in national initiatives to improve the quality and access to molecular testing for children with cancer, including the NCI-funded Count Me In Study (Dana Farber, Broad Institute), the National Comprehensive Cancer Network, the National Institutes of Health, and the Children's Oncology Group.

This episode of Standard Deviation features Oliver Bogler in conversation with Dr Na Zhao, a cancer biologist caught in the crossfire of science, politics, and survival. Na's life reads like a brutal lab experiment in persistence.She grew up in China, lost her mother and aunt to breast cancer before she turned twelve, then came to the United States to chase science as both an immigrant and a survivor's daughter. She worked two decades to reach the brink of independence as a cancer researcher, only to watch offers and grants vanish in the political chaos of 2025.Oliver brings her story into sharp focus, tracing the impossible climb toward a tenure-track position and the human cost of a system that pulls the ladder up just as people like Na reach for it. This conversation pulls back the curtain on the NIH funding crisis, the toll on early-career scientists, and what happens when personal tragedy fuels professional ambition.Listeners will walk away with a raw sense of how fragile the future of cancer research really is, and why people like Na refuse to stop climbing.RELATED LINKSDr Zhao at Baylor College of MedicineDr Zhao on LinkedInDr Zhao's Science articleIndirect Costs explained by US CongressFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship inquiries, email podcast@matthewzachary.comSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

In this episode of the Epigenetics Podcast, we talked with Mo Motamedi from the Center for Cancer Research at Massachusetts General Hospital about his work on RNA-mediated epigenetic regulation. The Interview starts with Dr. Motamedi sharing his personal journey into the realm of biology, sparked by a familial inclination towards science and a challenge to excel in a field that initially felt daunting. His passion was ignited during a genetics class, as he recognized the quantitative nature of the discipline amidst the evolution of modern techniques like qPCR and high-throughput sequencing. Dr. Motamedi goes on to articulate the importance of understanding the interplay between genetics and broader biological systems, emphasizing that an insightful grasp of evolution is vital for decoding cellular mechanisms. He reflects on his time in a postdoctoral lab under Danish Moazet, investigating RNA interference (RNAi) and its unexpected nuclear roles, contributing significantly to the understanding of how RNAi is involved in gene silencing via chromatin interaction. As his narrative unfolds, Dr. Motamedi provides deep insights into his own lab's work, which focuses on the establishment and maintenance of epigenetic states and their implications in cancer epigenetics. He discusses groundbreaking discoveries related to RNAi and heterochromatin, detailing experiments that unveil how specific proteins contribute to transcriptional and post-transcriptional gene silencing. A pivotal theme emerges: the complex dynamics of genome evolution and chromatin organization can be reshaped under various biological contexts, including the quiescent state of cells under stress. Moreover, the discussion traverses recent publications from Dr. Motamedi's lab, revealing how they identify long non-coding RNAs that function as silencers at centromeres, an essential mechanism that aids in the establishment of heterochromatin independently of RNAi. His findings advocate for the idea that well-structured genome organization can lead to more efficient gene regulation, which can also be crucial in therapeutic contexts for various cancers. References Motamedi, M. R., Hong, E. J., Li, X., Gerber, S., Denison, C., Gygi, S., & Moazed, D. (2008). HP1 proteins form distinct complexes and mediate heterochromatic gene silencing by nonoverlapping mechanisms. Molecular cell, 32(6), 778–790. https://doi.org/10.1016/j.molcel.2008.10.026 Joh, R. I., Khanduja, J. S., Calvo, I. A., Mistry, M., Palmieri, C. M., Savol, A. J., Ho Sui, S. J., Sadreyev, R. I., Aryee, M. J., & Motamedi, M. (2016). Survival in Quiescence Requires the Euchromatic Deployment of Clr4/SUV39H by Argonaute-Associated Small RNAs. Molecular cell, 64(6), 1088–1101. https://doi.org/10.1016/j.molcel.2016.11.020 Joh, R. I., Lawrence, M. S., Aryee, M. J., & Motamedi, M. (2021). Gene clustering drives the transcriptional coherence of disparate biological processes in eukaryotes. Systems Biology. https://doi.org/10.1101/2021.04.17.440292 Related Episodes Evolutionary Forces Shaping Mammalian Gene Regulation (Emily Wong) Chromatin Evolution (Arnau Sebé-Pedrós) The Role of lncRNAs in Tumor Growth and Treatment (Sarah Diermeier) Contact Epigenetics Podcast on Mastodon Epigenetics Podcast on Bluesky Dr. Stefan Dillinger on LinkedIn Active Motif on LinkedIn Active Motif on Bluesky Email: podcast@activemotif.com

This is the audio from my 10/1 YouTube Live, I'll discuss my 6 years as a full time reseller, the ups and downs, and whether I'd do it all again. I've also got news from eBay, Etsy, USPS and more!I'm riding in the Great Cycle Challenge to raise money for Kids' Cancer Research! I've pledged 300 miles in September! I'll do the miles, but I need you to give, please donate if you can! Thanks! ⁠⁠⁠https://greatcyclechallenge.com/riders/RyanShoemaker⁠⁠⁠My New Cycling Channel: ⁠⁠⁠https://www.youtube.com/@cycling-with-ryan⁠⁠⁠⁠⁠⁠⁠Cycling With Ryan Instagram ⁠⁠⁠https://www.instagram.com/cycling_with_ryan⁠⁠⁠My Website: ⁠⁠⁠https://linktr.ee/galaxycdsrocks⁠⁠⁠The YouTube Version of this show: ⁠⁠⁠https://www.youtube.com/@GalaxyCDSRocks⁠⁠⁠My Ebay Store: ⁠⁠⁠https://ebay.us/HD2CAs⁠⁠⁠My Curated eBay Supply Store: ⁠⁠⁠https://www.ebay.com/inf/galaxycdsrocks⁠⁠⁠My Etsy Shop: ⁠⁠⁠https://www.etsy.com/shop/GalaxyCDS⁠⁠⁠⁠⁠⁠⁠I've created a series of Reselling Logs, and Personal Journals, which you can see on Amazon! ⁠⁠⁠https://amzn.to/3pJPkqD⁠⁠⁠Galaxy CDS Rocks Swag Store: ⁠⁠⁠galaxy-cds-rocks-and-flips.printify.me/products⁠⁠⁠Donations to the channel accepted at: ⁠⁠⁠https://www.paypal.me/galaxycds⁠⁠⁠My Channel Ethics Statement Regarding Sponsorships: ⁠⁠⁠https://docs.google.com/document/d/1UmRx77pe_F9kmiG4VlkDuy8Kmq32hJvY1n2COf5ImZY/edit?usp=sharing⁠⁠⁠Stuff I use: (These are sponsored affiliate links, and by using them you will support the podcast when I receive a small commission payment from the site for referring you, at no additional cost to you. So click away Galaxians!)I use Streamyard for my Podcast Interviews and Upcoming Live Shows. I highly recommend it! ⁠⁠⁠https://bit.ly/49spdKc⁠⁠⁠Have a need to crosslist? Try ListPerfectly! I recently signed up and am in the process of moving over 6000 listings from eBay to Mercari, watch for future updates! Use this referral link, be sure to input referral code 634 and save 30% off your first month, please and thank you! ⁠⁠⁠https://listperfectly.com/?ref=634⁠⁠⁠Sign Up with Mercari! It's easy to buy and sell on Mercari. Get up to $30 when you get started. Use code RPSYYJ when you sign up with my link: ⁠⁠⁠https://merc.li/bWdhq8kVb #mercari⁠⁠⁠Podcast/YouTube GearOBSBOT Tiny 2 Lite Camera: ⁠⁠⁠https://amzn.to/40QVOYx⁠⁠⁠⁠⁠Elgato Stream Deck: ⁠⁠⁠https://amzn.to/468lvHE⁠⁠⁠⁠⁠Hollyland Lark M2 Microphone: ⁠⁠⁠https://amzn.to/44IELcf⁠⁠⁠Reselling ToolsValue Mailers on eBay for All Of Your Package Needs: ⁠⁠⁠https://ebay.us/Sqif0E⁠⁠⁠⁠⁠beeprt Bluetooth 4x6 Thermal Label Printer: ⁠⁠⁠https://amzn.to/3Oiu61a⁠⁠⁠Scotty Peeler Label Remover: ⁠⁠⁠https://amzn.to/3rnpp8n⁠⁠⁠Tape King Tape Gun: ⁠⁠⁠https://amzn.to/2WjFPBz⁠⁠⁠Sound effects obtained from ⁠⁠⁠https://www.zapsplat.com

Wrapping up their learnings from HubSpot's INBOUND marketing conference in San Francisco earlier this month, Sam takes a breather while Claudia joins Roop on the mics once again to chat about email marketing. What's working? What's changing? What's new? Claudia and Roop recap three email marketing sessions they attended with friend of the podcast, Jay Schwedelson.From subject lines that work to formatting hacks, new stats bring clarity to what's ahead for email marketing, including insights on:Things not to do with AIThe incredible shelf life of some emails (it's WAY longer than you think)Why white space matters in email designThe continued anarchy Apple Mail is creating for marketersNew notes on emojisAnd moreAnd if you haven't already, pre-order Jay's new book, Stupider People Have Done It: Marketing Truths, Career Moves, and Life Advice for Doers. It's sure to be full of his trademark wit and wisdom—and proceeds go to The V Foundation for Cancer Research. A win-win for everyone.As always, thanks for listening. We're off next week (listen to this week's episode to hear why), but back with Sam and Roop the week after. See you then!—Claudia, Roop, and ChelseaTell us what you think!

In this episode of the Bench to Bedside podcast, Dr. Roy Jensen, vice chancellor and director of The University of Kansas Cancer Center, is joined by Dr. Anthony Sung and Dr. Jennifer Klemp, leaders in cancer survivorship research. They discuss their personal motivations, the importance of comprehensive survivorship care starting from diagnosis, and the innovative programs and research efforts at the KU Center for Survivorship and Patient-Oriented Research. The conversation highlights the challenges faced by cancer survivors, the need for individualized care, and the role of community support and research in improving survivor outcomes. The episode emphasizes KU Cancer Center's mission to become a national leader in patient-oriented survivorship care and research. 00:00 Introduction to Bench to Bedside 00:33 Exploring Cancer Survivorship 01:09 Personal Motivations in Cancer Research 04:21 Defining Cancer Survivorship 07:40 Vision for the KU Center for Survivorship and Patient Oriented Research 13:29 Future of Cancer Survivorship Research 26:45 Conclusion and Resources Links from this Episode: ·       Learn more about Dr. Anthony Sung ·       Learn more about Dr. Jennifer Klemp ·       Learn more about the KU Center for Survivorship and Patient-Oriented Research To ensure you get our latest updates, For the latest updates, follow us on the social media channel of your choice by searching for KU Cancer Center.  

Katie Henry has seen some things. From nonprofit bootstraps to Big Pharma boardrooms, she's been inside the machine—and still believes we can fix it. We go deep on her winding road from folding sweaters at J.Crew to launching a vibrator-based advocacy campaign that accidentally changed the sexual health narrative in breast cancer.Katie doesn't pull punches. She's a born problem solver with zero tolerance for pink fluff and performative empathy. We talk survivor semantics, band camp trauma, nonprofit burnout, and why “Didi” is the grandparent alter ego you never saw coming.She's Murphy Brown with a marimba. Veronica Sawyer in pharma. Carla Tortelli with an oncology Rolodex. And she still calls herself a learner.This is one of the most honest, hilarious, and refreshingly real conversations I've had. Period.RELATED LINKS:Katie Henry on LinkedInKatie Henry on ResearchGateLiving Beyond Breast CancerNational Breast Cancer CoalitionFEEDBACK:Like this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship inquiries, email podcast@matthewzachary.com.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Preview: Dr. Henry Miller celebrates vaccines for dramatically increasing longevity and eradicating diseases like polio. He notes the success of COVID-19 shots and criticizes the NIH for defunding promising mRNA cancer research. 1919

More than 50 years ago, President Richard Nixon declared war on cancer when he signed the National Cancer Act in 1971. Since then, the United States has emerged as a juggernaut in cancer research, funded largely by the government.But since President Donald Trump took office in January, the administration's sweeping cuts to the federal workforce and government funding are upending the country's research system.So, how are these funding and staffing cuts affecting cancer research and treatment? And how could they impact our progress towards scientific breakthroughs?Find more of our programs online. Listen to 1A sponsor-free by signing up for 1A+ at plus.npr.org/the1a. Learn more about sponsor message choices: podcastchoices.com/adchoicesNPR Privacy Policy

In this episode of Onc Now, Luis Paz-Ares, Chair of the Medical Oncology Department at Hospital Universitario 12 de Octubre in Madrid, Spain, shares his expert insights on the evolving science of lung cancer. From the critical role of prevention and smoking cessation through to the latest therapeutic breakthroughs, Paz-Ares offers a candid discussion on the progress, challenges, and hopes for the future of lung cancer research and treatment.  Timestamps:  00:00 – Introduction  01:09 – Key insights on lung cancers  02:26 – Luis's journey into oncology  04:10 – Highlights and lowlights of his role  08:30 – Delivering bad news to patients  10:30 – Current diagnosis process and treatment landscape  13:20 – Trends in lung cancer prevalence  16:00 – IMforte trial  21:15 – Biggest obstacles researchers and clinicians face today  22:50 – Non-smokers  24:40 – European Society for Medical Oncology (ESMO) 2025 predictions  26:00 – Luis's three wishes for cancer research    Disclaimer: The opinions expressed in this episode belong to the speakers and do not necessarily represent the opinions of EMJ.  

Some blood cancer patients are a facing a terminal disease prognisis after waiting so long for stem cell transplants their cancer is no longer curable. Piece meal funding and a lack of committment from health officials is to blame according to one specialist. The health minister has conceded the long wait times mean some blood cancer patients are enduring additional rounds of chemotherapy to keep the disease at bay. While others have had to wait so long their only option is palliative care. Director of the Centre for Cancer Research at the University of Auckland School of Medicine Professor Peter Browett spoke to Lisa Owen.

Brain tumors are the leading cause of pediatric cancer-related death. In August, the Trump administration announced it would stop supporting a federally funded network dedicated to researching these deadly cancers. Misha Mehta, president of the Neev Kolte & Brave Ronil Foundation, and Dr. Paul Graham Fisher join Ali Rogin to discuss the implications of the loss of funding. PBS News is supported by - https://www.pbs.org/newshour/about/funders. Hosted on Acast. See acast.com/privacy

Brain tumors are the leading cause of pediatric cancer-related death. In August, the Trump administration announced it would stop supporting a federally funded network dedicated to researching these deadly cancers. Misha Mehta, president of the Neev Kolte & Brave Ronil Foundation, and Dr. Paul Graham Fisher join Ali Rogin to discuss the implications of the loss of funding. PBS News is supported by - https://www.pbs.org/newshour/about/funders. Hosted on Acast. See acast.com/privacy

This is the audio from the Wednesday 9/17 YouTube live discussing upcoming changes at Etsy, Poshmark, and more.I'm riding in the Great Cycle Challenge to raise money for Kids' Cancer Research! I've pledged 300 miles in September! I'll do the miles, but I need you to give, please donate if you can! Thanks! ⁠⁠https://greatcyclechallenge.com/riders/RyanShoemaker⁠⁠My New Cycling Channel: ⁠⁠https://www.youtube.com/@cycling-with-ryan⁠⁠⁠⁠Cycling With Ryan Instagram ⁠⁠https://www.instagram.com/cycling_with_ryan⁠⁠My Website: ⁠⁠https://linktr.ee/galaxycdsrocks⁠⁠The YouTube Version of this show: ⁠⁠https://www.youtube.com/@GalaxyCDSRocks⁠⁠My Ebay Store: ⁠⁠https://ebay.us/HD2CAs⁠⁠My Curated eBay Supply Store: ⁠⁠https://www.ebay.com/inf/galaxycdsrocks⁠⁠My Etsy Shop: ⁠⁠https://www.etsy.com/shop/GalaxyCDS⁠⁠⁠⁠I've created a series of Reselling Logs, and Personal Journals, which you can see on Amazon! ⁠⁠https://amzn.to/3pJPkqD⁠⁠Galaxy CDS Rocks Swag Store: ⁠⁠galaxy-cds-rocks-and-flips.printify.me/products⁠⁠Donations to the channel accepted at: ⁠⁠https://www.paypal.me/galaxycds⁠⁠My Channel Ethics Statement Regarding Sponsorships: ⁠⁠https://docs.google.com/document/d/1UmRx77pe_F9kmiG4VlkDuy8Kmq32hJvY1n2COf5ImZY/edit?usp=sharing⁠⁠Stuff I use: (These are sponsored affiliate links, and by using them you will support the podcast when I receive a small commission payment from the site for referring you, at no additional cost to you. So click away Galaxians!)I use Streamyard for my Podcast Interviews and Upcoming Live Shows. I highly recommend it! ⁠⁠https://bit.ly/49spdKc⁠⁠Have a need to crosslist? Try ListPerfectly! I recently signed up and am in the process of moving over 6000 listings from eBay to Mercari, watch for future updates! Use this referral link, be sure to input referral code 634 and save 30% off your first month, please and thank you! ⁠⁠https://listperfectly.com/?ref=634⁠⁠Sign Up with Mercari! It's easy to buy and sell on Mercari. Get up to $30 when you get started. Use code RPSYYJ when you sign up with my link: ⁠⁠https://merc.li/bWdhq8kVb #mercari⁠⁠Podcast/YouTube GearOBSBOT Tiny 2 Lite Camera: ⁠⁠https://amzn.to/40QVOYx⁠⁠Elgato Stream Deck: ⁠⁠https://amzn.to/468lvHE⁠⁠Hollyland Lark M2 Microphone: ⁠⁠https://amzn.to/44IELcf⁠⁠Reselling ToolsValue Mailers on eBay for All Of Your Package Needs: ⁠⁠https://ebay.us/Sqif0E⁠⁠beeprt Bluetooth 4x6 Thermal Label Printer: ⁠⁠https://amzn.to/3Oiu61a⁠⁠Scotty Peeler Label Remover: ⁠⁠https://amzn.to/3rnpp8n⁠⁠Tape King Tape Gun: ⁠⁠https://amzn.to/2WjFPBz⁠⁠Sound effects obtained from ⁠⁠https://www.zapsplat.com

Sophie Sargent walked into the studio already owning the mic. A pandemic-era media rebel raised in New Hampshire, trained in Homeland Security (yep), and shaped by rejection, she's built a career out of DM'ing her way into rooms and then owning them. At 25, she's juggling chronic illness, chronic overachievement, and a generation that gets dismissed before it even speaks.We talk Lyme disease, Lyme denial, and the healthcare gaslighting that comes when you “look fine” but your body says otherwise. We dive into rejection as a career accelerant, mental health as content porn, and what it means to chase purpose without sacrificing identity. Sophie's a former morning radio host, country music interviewer, and Boston-based creator with a real voice—and she uses it.No fake podcast voice. No daddy-daughter moment. Just two loudmouths from different planets figuring out what it means to be seen, believed, and taken seriously in a system designed to do the opposite.Spoiler: She's smarter than I was at 25. And she'll probably be your boss someday.RELATED LINKSSophie on InstagramSophie on YouTubeSophie on LinkedInMedium article: “Redefining Rejection”See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

What happens when you hand a mic to the most extroverted, uncensored Gen Z career coach in New York? You get Olivia Battinelli—adjunct professor, student advisor, mentor, speaker, and unfiltered truth-teller on everything from invisible illness to resume crimes.We talked about growing up Jewish-Italian in Westchester, surviving the Big Four's corporate Kool-Aid, and quitting a job after 7 months because the shower goals weren't working out. She runs NYU Steinhardt's internship program by day, roasts Takis and “rate my professor” trolls by night, and somehow makes room for maple syrup takes, career coaching, and a boyfriend named Dom who sounds like a supporting character from The Sopranos.She teaches kids how to talk to humans. She's allergic to BS. And she might be the most Alexis Rose-meets-Maeve Wiley-mashup ever dropped into your feed. Welcome to her first podcast interview. It's pure gold.RELATED LINKS:Olivia Battinelli on LinkedInOlivia's Liv It Up Coaching WebsiteOlivia on InstagramNYU Steinhardt Faculty PageFEEDBACK:Like this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship inquiries, email podcast@matthewzachary.com.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

The B Team is back for NFL Week 2 following a big win from the Green Bay Packers on Thursday Night Football. Kick off the show with a look in on the Kansas City Chiefs and if Patrick Mahomes can get this team back up to a Super Bowl level this season. Is Dan Campbell in over his head without his play callers? Mike had the best weekend of his life in recent times watching the New York Jets lose in a nail biter to Aaron Rodgers. Finish off the show with some Mortal Locks!Remember to Subscribe! All new subscribers = $1 donation to Children's Cancer Research through the NFL season!Concern in Kansas City (00:01:10-00:08:50)Dolphins Need a Change (00:08:55-00:16:10)Jaxson Dart Time in New York (00:16:15-00:26:10)Dan Campbell is Lost (00:26:15-00:29:30)Who is Bouncing Back in NFC (00:29:35-00:36:50)State of the New York Jets (00:36:55-00:43:50)NFL Week 2 Mortal Locks (00:43:55-00:46:45)

The high cost associated with cancer diagnosis, treatment, and survivorship makes the burden of financial toxicity an unavoidable reality for many patients—and makes financial navigators central to the delivery of high-quality cancer care. In this vodcast episode, CANCER BUZZ speaks with Heather Simpson, BCPA, patient financial navigator lead, who shares her experience using the ACCC Financial Advocacy Network's financial advocacy services guidelines assessment tool to pinpoint financial navigation challenges within her cancer program. Heather Simpson, BCPA Patient Financial Navigator Lead              Allina Health Cancer Institute   River Falls, WI “When [ACCC] came out with a gap assessment tool in 2024...it allowed us to see where we had hit the mark with our program and where we had some gaps we could take care of to really be in line with the [Financial Advocacy Network's] guidelines.” Resources: Financial Advocacy Guidelines Financial Advocacy Services Assessment Tool Financial Advocacy Services Guidelines Assessment Tool User Guide In the Field: Practical Financial Advocacy Strategies for Supporting Cancer Patients Oncology Reimbursement Meetings This podcast is made possible by funding and support provided by Genentech, Eisai, Pfizer, and Regeneron and in partnership with AONN+, NPAF, Triage Cancer, and CancerCare.  

This episode is sponsored by Invivyd, Inc.Marc Elia is a biotech investor, the Chairman of the Board at Invivyd, and a Long COVID patient who decided to challenge the system while still stuck inside it. He's not here for corporate platitudes, regulatory shoulder shrugs, or vaccine-era gaslighting. This is not a conversation about politics, but it's about power and choice and the right to receive care and treatment no matter your condition.In this episode, we cover everything from broken clinical pathways to meme coins and the eternal shame of being old enough to remember Eastern Airlines. Marc talks about what it means to build tools instead of just complaining, what Long COVID has done to his body and his patience, and why the illusion of “choice” in healthcare is a luxury most patients don't have.This conversation doesn't ask for empathy. It demands it.RELATED LINKSMarc Elia on LinkedInInvivyd Company SiteMarc's Bio at InvivydFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship inquiries, email podcast@matthewzachary.comSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

On the latest episode of the GZERO World podcast, Ian Bremmer talks with world-renowned cancer researcher and Pulitzer Prize-winning author Siddhartha Mukherjee about the future of medicine—and why artificial intelligence might finally tip the scales in the decades-long war on cancer.Cancer remains the second leading cause of death in the US, killing nearly 1,700 people every day. But Mukherjee says AI is already reshaping the field, from radiology and diagnostics to identifying new carcinogens and designing entirely new cancer drugs. “Every time we do this in collaboration with a machine,” he explains, “the machine learns it, and it learns it forever.”In a wide-ranging conversation, Mukherjee breaks down three major areas where AI is advancing medicine: patient care, data mining, and generative drug development. He also weighs in on early cancer detection, how inflammation may hold the key to understanding new carcinogens, and why this moment may be the most hopeful in half a century of cancer research.Host: Ian BremmerGuest: Siddhartha Mukherjee Subscribe to the GZERO World with Ian Bremmer Podcast on Apple Podcasts, Spotify, or your preferred podcast platform, to receive new episodes as soon as they're published.

After years of carrying the weight of lead, Shannon and Cooper find a path out from under the darkness and into the sunlight.LEAD: how this story ends is up to us is an audio docudrama series that tells the true story of one child, his mysterious lead poisoning, and his mother's unwavering fight to keep him safe. A true story written by Shannon Burkett. Directed by Alan Taylor. Starring Merritt Wever, Alessandro Nivola, Cynthia Nixon, and Cooper Burkett.Lead was produced by Shannon Burkett. Co-produced by Jenny Maguire. Featuring Amy Acker, Tom Butler, Dennis T. Carnegie, James Carpinello, Geneva Carr, Dann Fink, Alice Kris, Adriane Lenox, Katie O'Sullivan, Greg Pirenti, Armando Riesco, Shirley Rumierk, Thom Sesma, and Lana Young. Music by Peter Salett. “Joy In Resistance” written by Abena Koomson-Davis and performed by Resistance Revival Chorus. Casting by Alaine Alldaffer and Lisa Donadio. Sound Design by Andy Kris. Recording Engineer Krissopher Chevannes.For corresponding visuals and more information on how to protect children from lead exposure please go to https://endleadpoisoning.org.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

President Trump has proposed cutting $2.5 billion from the National Cancer Institute, which in addition to cuts to the National Institutes of Health and research universities almost makes you wonder: whose side is he on in the fight against cancer?  Guest: Angus Chen, cancer reporter for STAT news Want more What Next TBD? Subscribe to Slate Plus to access ad-free listening to the whole What Next family and all your favorite Slate podcasts. Subscribe today on Apple Podcasts by clicking “Try Free” at the top of our show page. Sign up now at slate.com/whatnextplus to get access wherever you listen. Learn more about your ad choices. Visit megaphone.fm/adchoices

President Trump has proposed cutting $2.5 billion from the National Cancer Institute, which in addition to cuts to the National Institutes of Health and research universities almost makes you wonder: whose side is he on in the fight against cancer?  Guest: Angus Chen, cancer reporter for STAT news Want more What Next TBD? Subscribe to Slate Plus to access ad-free listening to the whole What Next family and all your favorite Slate podcasts. Subscribe today on Apple Podcasts by clicking “Try Free” at the top of our show page. Sign up now at slate.com/whatnextplus to get access wherever you listen. Learn more about your ad choices. Visit megaphone.fm/adchoices